Trevi Therapeutics, Inc. Share Price
NASDAQ: TRVI | Mid CapTrevi Therapeutics, Inc. Stock Performance
Open $17.50 | Prev. Close $17.98 | Circuit Range N/A |
Day Range $16.64 - $17.50 | Year Range $6.94 - $20.14 | Volume 1,08,775 |
Average Traded $16.92 |
Trevi Therapeutics, Inc. Share Price Today
As of 29 August 2026, Trevi Therapeutics, Inc.'s share price is $16.78. The stock opened at $17.50, compared to its previous close of $17.98. During today's trading session, Trevi Therapeutics, Inc.'s share price traded between $16.64 and $17.50, with an average price of $17.07. Over the past 52 weeks, the stock has recorded a high of $20.14 and a low of $6.94. In terms of performance, Trevi Therapeutics, Inc.'s share price has risen by 40.95% over the last six months and is up 131.45% on a year-on-year basis.
Trevi Therapeutics, Inc. Share Price Chart
Trevi Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $2.26B | PE Ratio (TTM) -52.44 | Dividend Yield N/A |
EPS (TTM) $-0.32 | Revenue (TTM) N/A | Return On Equity (TTM) -23.33% |
Profit Margin N/A | Debt to Equity 0.05 | Quarterly Earnings Growth YoY 10.87% |
Trevi Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Trevi Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Trevi Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $17.99 | $17.96 | -1.64% |
Jul 2026 | $18.70 | $18.26 | -2.01% |
Jun 2026 | $13.88 | $18.64 | +31.79% |
May 2026 | $13.78 | $14.14 | +2.84% |
Apr 2026 | $11.98 | $13.75 | +15.26% |
Mar 2026 | $12.09 | $11.93 | +0.21% |
Feb 2026 | $10.51 | $11.90 | +13.65% |
Jan 2026 | $12.38 | $10.47 | -16.23% |
Dec 2025 | $13.13 | $12.51 | -5.12% |
Nov 2025 | $11.73 | $13.18 | +13.08% |
Oct 2025 | $9.11 | $11.65 | +27.24% |
Sep 2025 | $7.25 | $9.16 | +26.34% |
TRVI Share Price FAQs
What is Trevi Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Trevi Therapeutics, Inc. stock?
What is TRVI's market capitalisation today?
What is TRVI's net income for the last quarter?
What is the 5 year returns of TRVI?
What is the high & low stock price of TRVI today?
Can I buy TRVI shares in India?